Injectafer
Payments companies reported to CMS as associated with Injectafer. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Injectafer, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Injectafer
These are the largest totals companies reported as associated with Injectafer. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Alexander Barsouk | Pittsburgh, PA | Hematology & Oncology | $111,496.12 |
| Draupadi Talreja | Northridge, CA | Hematology & Oncology | $108,257.80 |
| Nassir Azimi | La Mesa, CA | Cardiovascular Disease | $107,597.22 |
| Satheesh Kathula | Kettering, OH | Hematology & Oncology | $60,605.92 |
| Gates Colbert | Dallas, TX | Nephrology (Internal Medicine) | $51,466.75 |
| Ahmed Sawas | New York, NY | Hematology (Internal Medicine) | $49,771.17 |
| Lee Shulman | Chicago, IL | Obstetrics & Gynecology | $34,140.45 |
| Mohit Narang | Owing Mills, MD | Medical Oncology | $29,244.59 |
| Faisal Musa | Dearborn, MI | Hematology & Oncology | $28,468.81 |
| Kumar Abhishek | Mechanicsville, VA | Internal Medicine | $25,350.61 |
Prescribed Injectafer?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.